Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart Transplantation

Heart Lung and Circulation

Volumn 26, Issue 2, 2017, Pages 143-149

  Zabarovskaja, Stanislava ^a,b   Hage, Camilla ^a,b   Gabrielsen, Anders ^a   Mellbin, Linda ^a,b   Lund, Lars H ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Copeptin; Heart assist device; Heart failure; Heart transplantation

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; COPEPTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HEMOGLOBIN; SODIUM; VASOPRESSIN; WARFARIN; GLYCOPEPTIDE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANAMNESIS; ARTICLE; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INDEX; HEART OUTPUT; HEART TRANSPLANTATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KAPLAN MEIER METHOD; LEFT VENTRICULAR ASSIST DEVICE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEAN ARTERIAL PRESSURE; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGRESSION ANALYSIS; BLOOD; DISEASE FREE SURVIVAL; FOLLOW UP; HEART ASSIST DEVICE; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 84982153362     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2016.05.119     Document Type: Article

References (30)

1. [1] Schrier, R.W., Abraham, W.T., Hormones and hemodynamics in heart failure. N Engl J Med. 341:8 (1999), 577–585 Epub 1999/08/19.
2. [2] Francis, G.S., Goldsmith, S.R., Levine, T.B., Olivari, M.T., Cohn, J.N., The neurohumoral axis in congestive heart failure. Ann Intern Med. 101:3 (1984), 370–377 Epub 1984/09/01.
3. [3] Pruszczynski, W., Vahanian, A., Ardaillou, R., Acar, J., Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab. 58:4 (1984), 599–605 Epub 1984/04/01.
4. [4] Birnbaumer, M., Vasopressin receptors. Trends Endocrinol Metab. 11:10 (2000), 406–410 Epub 2000/11/25.
5. [5] Morgenthaler, N.G., Struck, J., Jochberger, S., Dunser, M.W., Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 19:2 (2008), 43–49 Epub 2008/02/23.
6. [6] Morgenthaler, N.G., Struck, J., Alonso, C., Bergmann, A., Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 52:1 (2006), 112–119 Epub 2005/11/05.
7. [7] Gegenhuber, A., Struck, J., Dieplinger, B., Poelz, W., Pacher, R., Morgenthaler, N.G., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 13:1 (2007), 42–49 Epub 2007/03/07.
8. [8] Masson, S., Latini, R., Carbonieri, E., Moretti, L., Rossi, M.G., Ciricugno, S., et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 12:4 (2010), 338–347 Epub 2010/01/26.
9. [9] Balling, L., Kistorp, C., Schou, M., Egstrup, M., Gustafsson, I., Goetze, J.P., et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail. 18:5 (2012), 351–358 Epub 2012/05/05.
10. [10] Lund, L.H., Matthews, J., Aaronson, K., Patient selection for left ventricular assist devices. Eur J Heart Fail. 12:5 (2010), 434–443 Epub 2010/02/23.
11. [11] Gabrielsen, A., Videbaek, R., Schou, M., Damgaard, M., Kastrup, J., Norsk, P., Non-invasive measurement of cardiac output in heart failure patients using a new foreign gas rebreathing technique. Clin Sci (Lond). 102:2 (2002), 247–252 Epub 2002/02/09.
12. [12] Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130:6 (1999), 461–470 Epub 1999/03/13.
13. [13] Terzic, D., Johansson-Fällgren, A.S., Ragnarsson, O., Goetze, J.P., Hammarsten, O., Evaluation of a Sensitive Copeptin Assay for Clinical Measurement. The Open Clinical Chemistry Journal. 5 (2012), 21–26.
14. [14] Iversen, K., Gotze, J.P., Dalsgaard, M., Nielsen, H., Boesgaard, S., Bay, M., et al. Risk stratification in emergency patients by copeptin. BMC medicine., 12.(80), 2014.
15. [15] Pocock, S.J., Ariti, C.A., McMurray, J.J., Maggioni, A., Kober, L., Squire, I.B., et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 34:19 (2013), 1404–1413 Epub 2012/10/26.
16. [16] Sartipy, U., Dahlstrom, U., Edner, M., Lund, L.H., Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 16:2 (2014), 173–179 Epub 2014/01/28.
17. [17] James, K.B., McCarthy, P.M., Thomas, J.D., Vargo, R., Hobbs, R.E., Sapp, S., et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation. 92:9 Suppl (1995), II191–II195 Epub 1995/11/01.
18. [18] James, K.B., McCarthy, P.M., Jaalouk, S., Bravo, E.L., Betkowski, A., Thomas, J.D., et al. Plasma volume and its regulatory factors in congestive heart failure after implantation of long-term left ventricular assist devices. Circulation. 93:8 (1996), 1515–1519 Epub 1996/04/15.
19. [19] Katan, M., Morgenthaler, N., Widmer, I., Puder, J.J., Konig, C., Muller, B., et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinology Letters. 29:3 (2008), 341–346 Epub 2008/06/27.
20. [20] Gabrielsen, A., Bie, P., Holstein-Rathlou, N.H., Christensen, N.J., Warberg, J., Dige-Petersen, H., et al. Neuroendocrine and renal effects of intravascular volume expansion in compensated heart failure. Am J Physiol Regul Integr Comp Physiol. 281:2 (2001), R459–R467 Epub 2001/07/13.
21. [21] Gabrielsen, A., Sorensen, V.B., Pump, B., Galatius, S., Videbaek, R., Bie, P., et al. Cardiovascular and neuroendocrine responses to water immersion in compensated heart failure. Am J Physiol Heart Circ Physiol. 279:4 (2000), H1931–H1940 Epub 2000/09/29.
22. [22] Miller, W.L., Grill, D.E., Struck, J., Jaffe, A.S., Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. Am J Cardiol. 111:6 (2013), 880–885 Epub 2013/01/02.
23. [23] Schrier, R.W., Martin, P.Y., Recent advances in the understanding of water metabolism in heart failure. Advances in Experimental Medicine and Biology. 449 (1998), 415–426 Epub 1999/02/23.
24. [24] Walker, B.R., Childs, M.E., Adams, E.M., Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol. 255:2 Pt 2 (1988), H261–H265 Epub 1988/08/01.
25. [25] Goldsmith, S.R., Francis, G.S., Cowley, A.W. Jr., Goldenberg, I.F., Cohn, J.N., Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol. 8:4 (1986), 779–783 Epub 1986/10/01.
26. [26] Nakamura, Y., Haneda, T., Osaki, J., Miyata, S., Kikuchi, K., Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. European Journal of Pharmacology. 391:1–2 (2000), 39–48 Epub 2000/03/18.
27. [27] Yamazaki, T., Izumi, Y., Nakamura, Y., Yamashita, N., Fujiki, H., Osada-Oka, M., et al. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail. 5:6 (2012), 794–802 Epub 2012/09/18.
28. [28] Goldsmith, S.R., Vasopressin as vasopressor. The American Journal of Medicine. 82:6 (1987), 1213–1219 Epub 1987/06/01.
29. [29] Vondrakova, D., Malek, F., Ostadal, P., Vranova, J., Miroslav, P., Schejbalova, M., et al. Correlation of NT-proBNP, proANP and novel biomarkers: copeptin and proadrenomedullin with LVEF and NYHA in patients with ischemic CHF, non-ischemic CHF and arterial hypertension. Int J Cardiol. 150:3 (2011), 343–344 Epub 2011/06/07.
30. [30] Bhandari, S.S., Loke, I., Davies, J.E., Squire, I.B., Struck, J., Ng, L.L., Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 116:3 (2009), 257–263 Epub 2008/07/24.